- Home
- MLYS vs SIGA Comparison
MLYS vs SIGA Comparison
Compare MLYS & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- SIGA
- Stock Information
- Founded
- MLYS 2019
- SIGA 1995
- Country
- MLYS United States
- SIGA United States
- Employees
- MLYS N/A
- SIGA N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- SIGA Health Care
- Exchange
- MLYS Nasdaq
- SIGA Nasdaq
- Market Cap
- MLYS 609.7M
- SIGA 551.0M
- IPO Year
- MLYS 2023
- SIGA 1997
- Fundamental
- Price
- MLYS $12.34
- SIGA $5.94
- Analyst Decision
- MLYS Strong Buy
- SIGA
- Analyst Count
- MLYS 2
- SIGA 0
- Target Price
- MLYS $30.00
- SIGA N/A
- AVG Volume (30 Days)
- MLYS 163.5K
- SIGA 567.4K
- Earning Date
- MLYS 11-11-2024
- SIGA 11-07-2024
- Dividend Yield
- MLYS N/A
- SIGA 10.15%
- EPS Growth
- MLYS N/A
- SIGA N/A
- EPS
- MLYS N/A
- SIGA 1.20
- Revenue
- MLYS N/A
- SIGA $173,731,386.00
- Revenue This Year
- MLYS N/A
- SIGA $16.79
- Revenue Next Year
- MLYS N/A
- SIGA $15.08
- P/E Ratio
- MLYS N/A
- SIGA $4.94
- Revenue Growth
- MLYS N/A
- SIGA 399.31
- 52 Week Low
- MLYS $7.37
- SIGA $4.26
- 52 Week High
- MLYS $16.91
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- MLYS 47.76
- SIGA 38.74
- Support Level
- MLYS $11.19
- SIGA $5.62
- Resistance Level
- MLYS $12.57
- SIGA $6.23
- Average True Range (ATR)
- MLYS 0.80
- SIGA 0.43
- MACD
- MLYS -0.06
- SIGA -0.07
- Stochastic Oscillator
- MLYS 43.07
- SIGA 19.02
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.